Compare HCKT & XOMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HCKT | XOMA |
|---|---|---|
| Founded | 1991 | 1981 |
| Country | United States | United States |
| Employees | N/A | 14 |
| Industry | Professional Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 324.6M | 471.6M |
| IPO Year | 1998 | N/A |
| Metric | HCKT | XOMA |
|---|---|---|
| Price | $12.90 | $41.39 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 1 | 4 |
| Target Price | $17.00 | ★ $52.50 |
| AVG Volume (30 Days) | 205.3K | ★ 342.6K |
| Earning Date | 05-05-2026 | 05-08-2026 |
| Dividend Yield | ★ 3.67% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.46 | N/A |
| Revenue | ★ $285,862,000.00 | N/A |
| Revenue This Year | $2.55 | $24.59 |
| Revenue Next Year | $5.07 | N/A |
| P/E Ratio | ★ $28.38 | $29.64 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $12.19 | $22.29 |
| 52 Week High | $26.74 | $42.81 |
| Indicator | HCKT | XOMA |
|---|---|---|
| Relative Strength Index (RSI) | 44.46 | 72.12 |
| Support Level | $12.42 | $24.38 |
| Resistance Level | $14.67 | N/A |
| Average True Range (ATR) | 0.51 | 1.47 |
| MACD | -0.01 | -0.08 |
| Stochastic Oscillator | 28.37 | 76.72 |
The Hackett Group Inc is an IP platform-based Generative Artificial Intelligence (Gen AI) strategic consulting and executive advisory digital transformation firm. The Hackett Group provides dedicated expertise in Gen AI-enabled enterprise transformation services across the front, mid and back office areas, including its highly recognized Oracle, SAP, OneStream and Coupa implementation offerings. It operates in three segments Oracle Solutions, SAP Solutions, and Global S&BT. It generates the majority of its revenue from the Global S&BT segment in the United States.
XOMA Royalty Corp is a biotechnology royalty aggregator playing a role in helping biotech companies achieve their goal of improving human health. XOMA acquires the potential future economics associated with pre-commercial therapeutic candidates. The Company's drug royalty aggregator business is mainly focused on the acquisition of early to mid-stage clinical assets. Geographically, the company operates in Switzerland, the United States, Asia Pacific, Europe, and other regions.